- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03692780
Careseng 1370 for Chemotherapy-Induced Myelosuppression
December 13, 2018 updated by: Careseng Biotech Co., Ltd.
A Phase I Dose-Finding Followed by Phase IIa Randomized, Double-Blind, Placebo-Controlled, Parallel, Add-on to Cisplatin Plus Docetaxel Study to Evaluate the Safety, Tolerability and Efficacy Profiles of Careseng 1370 to Treat Chemotherapy-Induced Myelosuppression in Advanced Non-Small Cell Lung Cancer (NSCLC) Subjects
This is a Phase I/IIa dose-finding (Phase I) followed by randomized, double-blind, placebo-controlled, parallel, add-on to cisplatin + docetaxel (Phase IIa) study to evaluate the safety, tolerability, and efficacy profiles of Careseng 1370 in subjects with advanced NSCLC.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 2
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Of either gender aged at least 20 years old
- Histologically or cytologically confirmed unresectable, locally advanced, metastatic untreated NSCLC and can be accurately assessed by computed tomography/magnetic resonance imaging (CT/MRI) scan (RECIST v1.1) for which regimen of cisplatin + docetaxel is arranged by the investigator; no prior chemotherapy treatment for this disease will be allowed.
- ECOG performance status score ≤2 and life expectancy ≥12 months
- Dated and signed informed consent
Exclusion Criteria:
- Had chemotherapy, therapeutic radiotherapy, or other therapy for NSCLC within 6 weeks before Screening visit
- Has undergone major surgery within 4 weeks before Screening visit
- With contraindications to MRI
- Has elective or planned surgery to be conducted during the trial
- Has documented brain or leptomeningeal metastases or any cancer other than NSCLC
- Inadequate hematologic function, as defined by: absolute neutrophil count (ANC) ≤ 1,500/µL; hemoglobin concentration < 10.0 g/dL; and platelet count ≤ 100,000/µL
- Inadequate hepatic function, as defined by: total bilirubin level > ULN; AST or ALT > 1.5 x ULN; gamma-GT > 2.5 x ULN; ALP > 2.5 x ULN.
- Inadequate renal function, as defined by: serum creatinine level > 1.5 x ULN; or calculated serum creatinine clearance (Cockcroft-Gault) < 50 mL/min
- Urinary protein >1+ on dipstick, edema or serum albumin < lower level of normal
- Any other ≥ grade 3 laboratory abnormality at baseline
- Inadequate coagulation function, as defined by: INR > 1.5 x ULN or aPTT > 1.5 x ULN
- Male subject with female spouse/partners who are of childbearing potential refuses to adopt highly effective contraceptives from Screening visit until 7 days after end of study treatment
- Female subjects with childbearing potential who is pregnant (confirmed by urine or serum pregnancy test) or lactating, refuses to adopt highly effective contraceptives, if heterosexually active, from Screening visit until 7 days after end of study treatment
- Requirement of anticoagulants, antiplatelet treatments (e.g., warfarin, heparins) from Screening visit until Final visit
- History of human immunodeficiency virus (HIV) infection
- Has experienced any grade 3 or 4 gastrointestinal bleeding within 12 weeks before Screening visit
- Has a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess <6 months before Screening visit, or the subject has a history of poorly controlled or recurrent inflammatory bowel disease (including Crohn's disease or ulcerative colitis)
- Has participated in a clinical study within 4 weeks prior to Screening visit
- Has a known allergy to investigational product Careseng 1370, matched placebo, cisplatin, docetaxel or their excipients. If there is suspicion that the subject may have an allergy, the subject should be excluded.
- Has known alcohol or drug dependency
- Requirement for ongoing immunosuppressive agents (including azathioprine, mycophenolate, cyclophosphamide, chlorambucil, methotrexate, cyclosporine) or systemic steroid with equivalent dosage higher than prednisolone 30 mg/day for more than 14 days
Significant cardiovascular disease, including:
- History of New York Heart Association (NYHA) class III or IV congestive heart failure
- Ongoing uncontrolled hypertension
- History of congenital long QT syndrome
- Ongoing prolonged corrected QT (QTc) interval defined as at least 450 msec
- History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation)
- Uncontrolled psychiatric disorder or altered mental status precluding informed consent or necessary testing per investigator's discretion
- Consumption of herbal preparations/supplements (except for a daily multivitamin/mineral supplement not containing herbal components) within 2 weeks prior to the start of cisplatin + docetaxel or Careseng 1370/matched placebo administration
- Is not considered to be suitable for this study, in the opinion of the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Careseng 1370
|
4,000mg granules in sachet
|
PLACEBO_COMPARATOR: Matched Placebo
|
4,000mg granules in sachet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum change of absolute neutrophil count (ANC) up to End of Treatment visit
Time Frame: Day 1, 8, 15 22, 29, 36, 43, 50, 57, 64, 71, 78, 85
|
End of Treatment will be Day 85
|
Day 1, 8, 15 22, 29, 36, 43, 50, 57, 64, 71, 78, 85
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects with anemia, neutropenia, or thrombocytopenia of all grades at post-treatment visits
Time Frame: Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85
|
Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85
|
|
Maximum change and by visit change in white blood cell (WBC) count from baseline to post-treatment visits
Time Frame: Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85
|
Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85
|
|
Maximum change and by visit change in platelet count from baseline to post-treatment visits
Time Frame: Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85
|
Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85
|
|
Maximum change and by visit change in red blood cell (RBC) count from baseline to post-treatment visits
Time Frame: Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85
|
Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85
|
|
Maximum change and by visit change in serum C-reactive protein (CRP) level from baseline to post-treatment visits
Time Frame: Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85
|
Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85
|
|
Maximum change and by visit change in absolute neutrophil count (ANC) from baseline to post-treatment visits
Time Frame: Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85
|
Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85
|
|
Objective response rate (ORR) defined as the proportion of subjects with CR or PR as best overall response evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 on MRI or CT results
Time Frame: Day 1, 43, 85
|
Day 1, 43, 85
|
|
Disease control rate (DCR) defined as the proportion of subjects with CR, PR, or SD as best overall response evaluated according to RECIST criteria version 1.1 on MRI or CT results
Time Frame: Day 1, 43, 85
|
Day 1, 43, 85
|
|
Proportion of subjects with complete response (CR), partial response (PR), stable disease (SD), and progression disease (PD) as best overall response evaluated according to RECIST criteria version 1.1 on MRI or CT results
Time Frame: Day 1, 43, 85
|
Day 1, 43, 85
|
|
Change in quality of life assessed by the Functional Assessment of Cancer Therapy Lung Cancer (FACT-L) total score from baseline to post-treatment visits
Time Frame: Day 1, 22, 43, 64, 85
|
FACT-L total score ranges from 0 to 144.
Higher values represent a worse outcome
|
Day 1, 22, 43, 64, 85
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
March 1, 2019
Primary Completion (ANTICIPATED)
March 1, 2021
Study Completion (ANTICIPATED)
June 1, 2021
Study Registration Dates
First Submitted
September 25, 2018
First Submitted That Met QC Criteria
September 30, 2018
First Posted (ACTUAL)
October 2, 2018
Study Record Updates
Last Update Posted (ACTUAL)
December 17, 2018
Last Update Submitted That Met QC Criteria
December 13, 2018
Last Verified
December 1, 2018
More Information
Terms related to this study
Other Study ID Numbers
- Careseng 1370-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chemotherapy-Induced Myelosuppression
-
Careseng Biotech Co., Ltd.UnknownChemotherapy-induced Myelosuppression
-
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.UnknownChemotherapy-induced Neutropenia | Myelosuppression
-
Myelo Therapeutics GmbHCompletedBreast Cancer | Myelosuppression | Chemotherapy-Induced NeutropeniaGermany
-
Taichung Tzu Chi HospitalCompleted
-
Aileron Therapeutics, Inc.TerminatedPrevention of Chemotherapy-induced MyelosuppressionUnited States, Bosnia and Herzegovina, Serbia, Bulgaria
-
Lei LiUnknownGynecologic Cancer | Febrile Neutropenia | Chemotherapy-induced Neutropenia | Myelosuppression AdultChina
-
Taipei City HospitalCompletedChemotherapy-Induced ChangeTaiwan
-
Ziv HospitalUnknownMyelosuppressionIsrael
-
National Cheng-Kung University HospitalTerminatedChemotherapy-induced Abnormal Thermal SensationTaiwan
-
GlaxoSmithKlineCompletedChemotherapy-Induced Nausea and Vomiting | Nausea and Vomiting, Chemotherapy-InducedTaiwan, United States, Germany, Russian Federation, Spain, Ireland, Thailand, Hong Kong, Mexico, Philippines, Austria, Chile, Greece, Poland, Canada, Czech Republic, United Kingdom, Hungary, Pakistan, Slovakia, Singapore, Portugal, ... and more
Clinical Trials on Careseng 1370
-
Careseng Biotech Co., Ltd.UnknownChemotherapy-induced Myelosuppression